Adavivint
Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro; induces hMSC differentiation into mature, functional chondrocytes and decreases cartilage catabolic marker levels; significantly improves Osteoarthritis Research Society International (OARSI) histology scores and biomarkers in a rodent OA model.Rheumatoid Arthritis Phase 2 Clinical (In Vitro) :Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro. (In Vivo) :Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model.
Product Specifications
CAS Number
1467093-03-3
Product Name Alternative
SM-04690 | SM 04690 | SM04690
Purity
>98% (HPLC)
Solubility
DMSO : 25 mg/mL 49.45 mM
Smiles
CC (C) CC (=O) NC1=CN=CC (=C1) C2=CC3=C (C=C2) NN=C3C4=NC5=C (N4) C=NC=C5C6=CC (=CC=C6) F
Molecular Formula
C29H24FN7O
Molecular Weight
505.557
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N- (5-{3-[7- (3-fluorophenyl) -1H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl}pyridin-3-yl) -3-methylbutanamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TARSL2, ID (Probable Threonyl-tRNA Synthetase, Cytoplasmic, Threonine-tRNA Ligase, ThrRS, Threonyl-tRNA Synthetase-like Protein 2, TARSL2) (FITC)
TARSL2, ID (Probable Threonyl-tRNA Synthetase, Cytoplasmic, Threonine-tRNA Ligase, ThrRS, Threonyl-tRNA Synthetase-like Protein 2, TARSL2) (FITC)
Lentiviral mouse Rwdd2a shRNA (UAS) - Lentiviral mouse Rwdd2a shRNA (UAS, iRFP) (100)
